VintaBio, a life sciences company with unmatched industry expertise helping alleviate the viral vector bottleneck in cell and gene therapy development, today emerged from stealth with newly appointed CEO David Radspinner at its helm, $64 million in funding led by Decheng Capital, and a custom-built manufacturing facility in Philadelphia that is open and accepting orders. VintaBio was founded by Junwei Sun and Dr. Shangzhen Zhou, who developed the first viral vectors used for life-saving therapies, including the cell therapy that cured Emily Whitehead of a pediatric cancer, as well as the first two FDA-approved gene therapies.

VintaBio's development and manufacturing team has over a century of experience in the cell and gene therapy space and its members have played key roles in the development of the most advanced therapies on the market today. Located in Philadelphia - the epicenter of cell and gene therapy innovation - VintaBio specializes in developing and manufacturing consistent, high-quality viral vectors, a vital and currently underserved area of CGT development.